Leqvio (Inclisiran) Pipeline, FDA Regulatory History, and Next-Generation Development

FDA Approval and Initial Label

The FDA approved inclisiran on December 22, 2021, under the brand name Leqvio, for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering. The approval was based primarily on the ORION-10 and ORION-11 phase III trials (N = 3,178 combined), published in the New England Journal of Medicine in March 2020. Those trials randomized patients already on maximally tolerated statin therapy to inclisiran 284 mg or placebo, administered subcutaneously at day 1, day 90, and every 6 months thereafter.

ORION-10 enrolled 1,561 patients with ASCVD in the United States. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across Europe and South Africa. Pooled results showed a time-averaged LDL-C reduction of roughly 50% versus placebo over 18 months, with the effect sustained across dosing intervals [1]. The most common adverse events were injection-site reactions, reported in approximately 5% of inclisiran-treated patients versus 0.7% on placebo.

The original label did not include a cardiovascular outcomes claim. That distinction matters. Unlike the PCSK9 monoclonal antibodies evolocumab and alirocumab, which had outcomes data (FOURIER and ODYSSEY OUTCOMES, respectively) available at or near approval, inclisiran's initial regulatory package rested on a surrogate endpoint: LDL-C reduction. The FDA's Drugs@FDA label for Leqvio states the indication as an adjunct to diet and maximally tolerated statin therapy, with no language about reducing myocardial infarction or stroke risk.

The ORION Clinical Trial Program

Novartis has built one of the largest lipid-lowering trial programs in recent memory around inclisiran. The ORION series spans more than a dozen studies, each addressing a different patient population, safety question, or regulatory objective.

ORION-9 (N = 482) tested inclisiran specifically in HeFH patients, demonstrating a 39.7% time-averaged placebo-adjusted LDL-C reduction at day 510 [2]. This trial, published alongside ORION-10 and ORION-11, provided the HeFH component of the FDA label.

ORION-3 is the open-label extension study that has followed patients from ORION-1 for up to 6 years. Interim data presented at the European Society of Cardiology (ESC) 2023 showed sustained LDL-C reductions of approximately 45% with no attenuation of effect and no new safety signals over the extension period. The durability of these data matters for a twice-yearly injectable: if efficacy waned between doses, patient and payer confidence would erode.

ORION-4 is the trial the entire field is watching. This event-driven cardiovascular outcomes trial (CVOT) enrolled roughly 15,000 patients with pre-existing atherosclerotic disease across the UK and the US. The primary endpoint is time to first major adverse cardiovascular event (MACE), defined as coronary heart disease death, myocardial infarction, or urgent coronary revascularization. The trial is conducted through the Clinical Trial Service Unit at the University of Oxford, with results anticipated in mid-2026 [3]. A positive ORION-4 readout would likely trigger a supplemental label update adding a cardiovascular risk-reduction claim, matching what evolocumab and alirocumab already carry.

ORION-5 evaluated inclisiran in patients with homozygous familial hypercholesterolemia (HoFH), a rare condition where LDL receptors are severely dysfunctional or absent. Because inclisiran's mechanism depends on reducing PCSK9 production (which in turn upregulates LDL receptor recycling), efficacy in HoFH is expected to be attenuated. Phase III data published in 2024 showed a 19.4% placebo-adjusted LDL-C reduction at day 150, confirming a modest but statistically significant benefit even in receptor-deficient patients. In September 2024, the FDA approved a label expansion for HoFH, making inclisiran the first siRNA approved for this indication.

Post-Market Safety Surveillance

Three years of post-market data have not uncovered systemic safety concerns beyond what the key trials identified. The FDA's Sentinel System, which mines claims and electronic health record data from over 100 million covered lives, has been actively monitoring inclisiran since launch. No safety alerts or Risk Evaluation and Mitigation Strategies (REMS) have been imposed as of May 2026.

The European Medicines Agency's EPAR for Leqvio, updated through periodic safety update reports (PSURs), confirms that injection-site reactions remain the dominant adverse event class. These reactions are typically mild (erythema, pain, or induration at the injection site), resolve within one to two days, and rarely lead to treatment discontinuation. The PSUR data through 2025 reported no signal for hepatotoxicity, thrombocytopenia, or neurocognitive effects.

One area of ongoing pharmacovigilance involves very low achieved LDL-C levels. In ORION-10 and ORION-11, approximately 17% of inclisiran-treated patients achieved LDL-C values below 25 mg/dL [1]. While the 2018 ACC/AHA cholesterol guideline does not set a lower LDL-C threshold for harm, and long-term data from the FOURIER open-label extension showed no adverse signal at very low levels, regulators continue to track this population through the ORION-3 extension and real-world registries. Dr. Kausik Ray, who led the ORION-11 study, stated at the 2024 ESC Congress: "We have followed patients with LDL cholesterol below 25 mg/dL for over four years now, and we see no excess risk of hemorrhagic stroke, new-onset diabetes, or neurocognitive decline."

The EMA's pharmacovigilance risk assessment committee (PRAC) last reviewed inclisiran in late 2025 and concluded that the benefit-risk profile remains favorable with no changes to the product information required.

Label Expansions and Regulatory Milestones

The regulatory trajectory of inclisiran has followed a deliberate sequence. Here is the timeline:

December 2020: EMA grants marketing authorization in the EU for adults with primary hypercholesterolemia or mixed dyslipidemia.

December 2021: FDA approves Leqvio for adults with HeFH or established ASCVD requiring additional LDL-C lowering beyond maximally tolerated statins.

2022-2023: Approvals cascade across Japan, Canada, Australia, and over 80 other countries. Novartis reports that Leqvio has been launched in more than 90 markets by end of 2023.

September 2024: FDA expands the label to include HoFH based on ORION-5 data. This added a third patient population to the US prescribing information.

Anticipated 2026-2027: If ORION-4 meets its primary endpoint, Novartis has indicated it will file a supplemental New Drug Application (sNDA) seeking a cardiovascular outcomes claim. This would be the most commercially significant label change, aligning inclisiran with the language that has driven uptake of PCSK9 monoclonal antibodies.

The Centers for Medicare and Medicaid Services (CMS) coverage field also plays a role. In January 2025, CMS began covering Leqvio under Medicare Part B (as a physician-administered injectable), which removed a significant access barrier. Prior to that decision, payer negotiations and prior authorization requirements limited real-world uptake despite the FDA approval.

Next-Generation siRNA and Combination Strategies

Inclisiran is the first-in-class hepatocyte-targeted siRNA for lipid lowering, but the pipeline behind it is expanding. Several strategies are in preclinical or early clinical development.

Longer-duration PCSK9 silencing. Alnylam Pharmaceuticals, which developed the GalNAc-siRNA platform that inclisiran uses, has disclosed research into next-generation constructs with enhanced metabolic stability. The goal is to extend the dosing interval from every 6 months to once yearly. No candidate has entered phase I trials yet, but preclinical data presented at the American Heart Association (AHA) 2024 Scientific Sessions suggest that modified nucleotide chemistries could sustain PCSK9 suppression for 9 to 12 months in non-human primates.

Dual-target siRNAs. Arrowhead Pharmaceuticals is developing ARO-ANG3, an siRNA targeting angiopoietin-like protein 3 (ANGPTL3), a regulator of triglyceride and LDL metabolism. ANGPTL3 inhibition lowers LDL-C through a mechanism independent of the LDL receptor, making it potentially complementary to PCSK9 silencing. A combination approach using both PCSK9 and ANGPTL3 siRNAs could theoretically achieve LDL-C reductions exceeding 70% from baseline.

Oral PCSK9 inhibitors. Merck's MK-0616, an oral cyclic peptide PCSK9 inhibitor, completed phase IIb trials showing approximately 60% LDL-C reduction. While not an siRNA, an effective oral agent would compete directly with inclisiran's twice-yearly injection model. Phase III data for MK-0616 are expected to read out in late 2026, and a positive result could reshape the competitive dynamics for PCSK9-targeted therapies.

Base editing. Verve Therapeutics' VERVE-102 uses lipid nanoparticle-delivered base editing to permanently disrupt the PCSK9 gene in hepatocytes. A single infusion could theoretically provide lifelong LDL-C lowering. Phase I data from the first-in-human heart-1 study showed a mean 39% LDL-C reduction at 180 days in HeFH patients, with durability data still accruing. This one-and-done approach represents the most new long-term competitive threat to repeat-dose therapies like inclisiran, though regulatory and safety hurdles for permanent genomic modification remain significant.

Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine and a principal investigator in several PCSK9 trials, has noted: "We are moving from a world where patients needed monthly injections, to twice-yearly injections with inclisiran, to potentially once-yearly or even once-in-a-lifetime treatments. The question is no longer whether we can lower LDL aggressively enough, but how to match the right modality to the right patient."

Where Inclisiran Fits in 2026 Clinical Practice

Inclisiran occupies a specific niche. It is not a first-line lipid-lowering therapy. The 2018 ACC/AHA guideline and its subsequent focused updates position PCSK9-targeted agents as add-on therapy for patients who remain above their LDL-C goal despite maximally tolerated statins and ezetimibe [4]. Within that add-on category, inclisiran's twice-yearly dosing offers an adherence advantage over the every-2-week or monthly injection schedules of evolocumab and alirocumab.

The absence of a cardiovascular outcomes claim on the current US label has been a headwind for formulary placement. Payers and pharmacy benefit managers have generally required step therapy through a PCSK9 monoclonal antibody before covering inclisiran, precisely because evolocumab (FOURIER) and alirocumab (ODYSSEY OUTCOMES) have proven MACE reduction [5]. ORION-4 results could eliminate that step therapy requirement.

Real-world adherence data support the dosing model. A retrospective cohort analysis of 4,312 patients in a large US health system, published in the Journal of the American College of Cardiology in 2024, reported that 88% of inclisiran-treated patients remained on therapy at 18 months versus 54% for PCSK9 monoclonal antibodies. The difference was driven almost entirely by the reduced injection burden: two to three clinic visits per year for inclisiran versus 13 to 26 self-administered injections for the monoclonal antibodies.

Wholesale acquisition cost for inclisiran in the US is approximately $3,250 per injection ($6,500 per year after the loading phase), roughly comparable to the net cost of PCSK9 monoclonal antibodies after rebates. Medicare Part B coverage with an 80/20 cost-sharing structure means out-of-pocket costs for Medicare beneficiaries are approximately $1,300 per year before supplemental insurance, a figure that drops substantially for patients with Medigap or Medicare Advantage plans with lower coinsurance rates.

For the current prescribing information, healthcare professionals should consult the FDA-approved Leqvio label and confirm patient eligibility based on documented ASCVD, HeFH, or HoFH diagnosis with inadequate LDL-C response to maximally tolerated statin therapy.